Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic |
| |
Authors: | SK Thompson WW Smith B Zhao SM Halbert TA Tomaszek DG Tew MA Levy CA Janson KJ DAlessio MS McQueney J Kurdyla CS Jones RL DesJarlais SS Abdel-Meguid DF Veber |
| |
Affiliation: | Departments of Medicinal Chemistry, Structural Biology, Molecular Recognition, Protein Biochemistry, and Physical and Structural Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA. |
| |
Abstract: | Peptidomimetic cathepsin K inhibitors have been designed using binding models which were based on the X-ray crystal structure of an amino acid-based, active site-spanning inhibitor complexed with cathepsin K. These inhibitors, which contain a benzyloxybenzoyl group in place of a Cbz-leucine moiety, maintained good inhibitory potency relative to the amino acid-based inhibitor, and the binding models were found to be very predictive of relative inhibitor potency. The binding mode of one of the inhibitors was confirmed by X-ray crystallography, and the crystallographically determined structure is in close qualitative agreement with the initial binding model. These results strengthen the validity of a strategy involving iterative cycles of structure-based design, inhibitor synthesis and evaluation, and crystallographic structure determination for the discovery of peptidomimetic inhibitors. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|